Joseph Kekst
Gründer bei BoxCar Partners LLC
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Vincent Sandanayaka | M | - |
Nirogy Therapeutics, Inc.
 Nirogy Therapeutics, Inc. BiotechnologyHealth Technology Nirogy Therapeutics, Inc. is an American biotechnology company that operates in the healthcare industry. The company is based in N/A. The company was founded in 2014 by Vincent Sandanayaka, Jaime Escobedo. Simon C. Pedder has been the CEO of the company since 2022. | 10 Jahre |
| Mallory Morales | F | 40 | 3 Jahre | |
| Elan Ezickson | M | 60 |
Nirogy Therapeutics, Inc.
Nirogy Therapeutics, Inc. BiotechnologyHealth Technology Nirogy Therapeutics, Inc. is an American biotechnology company that operates in the healthcare industry. The company is based in N/A. The company was founded in 2014 by Vincent Sandanayaka, Jaime Escobedo. Simon C. Pedder has been the CEO of the company since 2022.
Asylia Therapeutics, Inc.
 Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Jaime Escobedo | M | - |
Nirogy Therapeutics, Inc.
Nirogy Therapeutics, Inc. BiotechnologyHealth Technology Nirogy Therapeutics, Inc. is an American biotechnology company that operates in the healthcare industry. The company is based in N/A. The company was founded in 2014 by Vincent Sandanayaka, Jaime Escobedo. Simon C. Pedder has been the CEO of the company since 2022. | 10 Jahre |
| Israel Makov | M | 85 |
Weizmann Institute of Science
| 17 Jahre |
| Andy Morse | M | 78 |
Weizmann Institute of Science
| - |
| Jeno Gyuris | M | 64 |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Ronald DePinho | M | 69 |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | 5 Jahre |
| Ann Berman | F | 71 | 3 Jahre | |
| Laurie Keating | F | 70 | 3 Jahre | |
| Gregg M. Steinberg | M | 61 |
Weizmann Institute of Science
| - |
| Karthik Radhakrishnan | M | 53 |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Michael Bookman | M | 37 | 3 Jahre | |
| Robert Z. Orlowski | M | - |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | 5 Jahre |
| Danna Azrieli | F | 57 |
Weizmann Institute of Science
| - |
| Casey Cunningham | M | - |
Nirogy Therapeutics, Inc.
Nirogy Therapeutics, Inc. BiotechnologyHealth Technology Nirogy Therapeutics, Inc. is an American biotechnology company that operates in the healthcare industry. The company is based in N/A. The company was founded in 2014 by Vincent Sandanayaka, Jaime Escobedo. Simon C. Pedder has been the CEO of the company since 2022. | - |
| Michal Schwartz | M | - |
Weizmann Institute of Science
| - |
| Yigal Landau | M | 64 |
Weizmann Institute of Science
| - |
| Avinoam Kadouri | M | - |
Weizmann Institute of Science
| - |
| Boaz Nadler | M | - |
Weizmann Institute of Science
| - |
| Irun Cohen | M | - |
Weizmann Institute of Science
| - |
| Naomi Sara Azrieli | M | 58 |
Weizmann Institute of Science
| - |
| Michel Revel | M | 85 |
Weizmann Institute of Science
| - |
| Theodore F. Perlman | M | - |
Weizmann Institute of Science
| - |
| Rachel Humphrey | M | 62 |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Gabriel Barbash | M | 74 |
Weizmann Institute of Science
| - |
| Adam Bly | M | - |
Weizmann Institute of Science
| - |
| Peter Feinberg | M | 63 | 3 Jahre | |
| Shimshon Harel | M | 77 |
Weizmann Institute of Science
| - |
| Avraham Berger | M | 72 |
Weizmann Institute of Science
| - |
| Anne-Marie Boucher | F | 58 |
Weizmann Institute of Science
| - |
| Eitan Neishlos | M | - |
Weizmann Institute of Science
| - |
| Karen Siem | F | - |
Weizmann Institute of Science
| - |
| Dan Yitzhak Gillerman | M | 80 |
Weizmann Institute of Science
| - |
| Jonathan Dorfan | M | - |
Weizmann Institute of Science
| - |
| Marina Sandler | F | - |
Weizmann Institute of Science
| - |
| Eyal Donald | M | - |
Weizmann Institute of Science
| - |
| Baruch Dener | M | - |
Weizmann Institute of Science
| - |
| Steve Tuck | M | - |
Weizmann Institute of Science
| - |
| Jeffrey Aronin | M | 56 |
Weizmann Institute of Science
| - |
| Yaron Silberberg | M | - |
Weizmann Institute of Science
| - |
| H. Thomas Beck | M | - |
Weizmann Institute of Science
| - |
| Roy J. Zuckerberg | M | 87 |
Weizmann Institute of Science
| - |
| Yossie Hollander | M | 66 |
Weizmann Institute of Science
| - |
| Ben Zion Landa | M | 78 |
Weizmann Institute of Science
| - |
| Deborah Salzberg | F | 70 |
Weizmann Institute of Science
| - |
| Richard E. Venn | M | 72 |
Weizmann Institute of Science
| - |
| Jonathan Steven Reich | M | 60 |
Weizmann Institute of Science
| - |
| Merle Allan Hinrich | M | 82 |
Weizmann Institute of Science
| - |
| Robert B. Machinist | M | 71 |
Weizmann Institute of Science
| - |
| Lucien Yehuda Bronicki | M | 88 |
Weizmann Institute of Science
| - |
| Simon Pedder | M | 63 |
Nirogy Therapeutics, Inc.
Nirogy Therapeutics, Inc. BiotechnologyHealth Technology Nirogy Therapeutics, Inc. is an American biotechnology company that operates in the healthcare industry. The company is based in N/A. The company was founded in 2014 by Vincent Sandanayaka, Jaime Escobedo. Simon C. Pedder has been the CEO of the company since 2022. | 2 Jahre |
| Martin S. Gerstel | M | 83 |
Weizmann Institute of Science
| - |
| Haim Aviv | M | 84 |
Weizmann Institute of Science
| - |
| Bruce Pollack | M | 65 |
Weizmann Institute of Science
| - |
| Hy Isenbaum | M | - |
Weizmann Institute of Science
| - |
| Enrico Tommaso Cucchiani | M | 74 |
Weizmann Institute of Science
| - |
| David Daneil Sieff | M | 78 |
Weizmann Institute of Science
| - |
| Yair Seroussi | M | 68 |
Weizmann Institute of Science
| - |
| Shimon Ullman | M | 76 |
Weizmann Institute of Science
| - |
| Robert Blum | M | 60 |
Weizmann Institute of Science
| - |
| Maurice Lévy | M | 82 |
Weizmann Institute of Science
| - |
| Barry Townsley | M | 77 |
Weizmann Institute of Science
| - |
| Gideon Hamburger | M | 80 |
Weizmann Institute of Science
| - |
| David Moross | M | - |
Weizmann Institute of Science
| - |
| Dan Propper | M | 83 |
Weizmann Institute of Science
| - |
| Alex M. Cranberg | M | - |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Doron Cohen | M | 71 |
Weizmann Institute of Science
| 25 Jahre |
| Avraham Bigger | M | 77 |
Weizmann Institute of Science
| 8 Jahre |
| Efrat Peled | F | 50 |
Weizmann Institute of Science
| - |
| Gurion Meltzer | M | - |
Weizmann Institute of Science
| - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Biren Amin | M | 51 | 1 Jahre | |
| Dennis McWilliams | M | 53 |
Nirogy Therapeutics, Inc.
Nirogy Therapeutics, Inc. BiotechnologyHealth Technology Nirogy Therapeutics, Inc. is an American biotechnology company that operates in the healthcare industry. The company is based in N/A. The company was founded in 2014 by Vincent Sandanayaka, Jaime Escobedo. Simon C. Pedder has been the CEO of the company since 2022. | 3 Jahre |
| Andrew Phillips | M | 53 | 1 Jahre | |
| Carolina Garcia Rizo | M | - | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Israel | 55 | 73,33% |
| Vereinigte Staaten | 20 | 26,67% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Joseph Kekst
- Persönliches Netzwerk
